Director-affiliated fund sells $127.4M in Cogent Biosciences stock

summarizeSummary

Fairmount Funds Management LLC, an entity affiliated with a director, executed a substantial open market sale of Cogent Biosciences stock totaling $127.4 million. This significant disposition, representing over 2% of the company's market capitalization, could signal a reduction in conviction from a key institutional investor and director-affiliated entity. The shares were sold at $36.40, below the current market price of $39.53. Investors should monitor for further insider activity or any related company announcements.

check_boxKey Events

• Significant Insider Sale

  Fairmount Funds Management LLC, an entity affiliated with a director, sold 3,500,000 shares of Cogent Biosciences common stock for a total value of $127,400,000.

• Substantial Stake Reduction

  The sale represents a significant portion of the company's market capitalization and reduces the reporting owner's common stock holdings to 5,503,418 shares post-transaction.

• Transaction Details

  The shares were sold at a price of $36.40 per share on January 22, 2026, which is below the current stock price of $39.53.

auto_awesomeAnalysis

Fairmount Funds Management LLC, an entity affiliated with a director, executed a substantial open market sale of Cogent Biosciences stock totaling $127.4 million. This significant disposition, representing over 2% of the company's market capitalization, could signal a reduction in conviction from a key institutional investor and director-affiliated entity. The shares were sold at $36.40, below the current market price of $39.53. Investors should monitor for further insider activity or any related company announcements.